

Erratum

Erratum to “Zoledronic acid: pharmacologic profile
of a potent bisphosphonate”
[*J. Organomet. Chem.* 690 (2005) 2439–2448]

Jonathan Green *

Novartis Institutes for BioMedical Research, WKL-125.901, Postfach CH-4002, Basel, Switzerland

Available online 19 August 2005

The correct title for Fig. 2 is “Relative potency of various bisphosphonates based on (a) inhibition of farnesyl diphosphate (FPP) synthase activity and (b) inhibition of calcium release by osteoclasts in murine calvaria cultures”.

The legend for Fig. 3 should read “Schematic diagram of the mevalonate pathway showing that inhibition of FPP synthase by nitrogen-containing bisphosphonates blocks synthesis of two isoprenoid lipid intermediates, farnesyl diphosphate and geranylgeranyl diphosphate, and induces the formation of a cytotoxic IPP–AMP conjugate. HMG CoA, 3-hydroxy 3-methylglutaryl coenzyme A; PP, diphosphate; AMP, adenosine monophosphate; Appp1, triphosphoric acid 1-adenosin-5′yl ester 3-[3-methylbut-3-enyl] ester; N-BPs, nitrogen-containing bisphosphonates. This figure was adapted with permission from Gober et al. [48a]”.

The following reference should be added as Ref. [48a]: H.J. Gober, M. Kistowska, L. Angman, P. Jenö, L. Mori, G. DeLibero, *J. Exp. Med.* 197 (2003) 163.

Additionally, Jonathan Green’s affiliation is with Novartis Institutes for BioMedical Research, not Novartis Pharma.

DOI of original article: [10.1016/j.jorganchem.2004.09.069](https://doi.org/10.1016/j.jorganchem.2004.09.069).

* Tel.: +41 61 696 4415; fax: +41 61 696 3849.

E-mail address: jonathan.gren@pharma.novartis.com.